Analysis of motor function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine

被引：0
|
作者：
Deberdt, W
De Deyn, PP
Carrasco, MM
Jeandel, C
Hay, DP
Feldman, PD
Young, CA
Lehman, DL
Breier, A
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
[2] Univ Antwerp, Dept Neurol, B-2020 Antwerp, Belgium
[3] Clin Psiquiatr Padre Menni, Pamplona, Spain
[4] CHU Montpellier, Hop La Colombiere, Internal Med & Geriatr Serv, Montpellier, France
来源：
JOURNAL OF PSYCHOPHARMACOLOGY | 2003年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A57 / A57
页数：1
相关论文
共 50 条
  • [31] Efficacy of Memantine for Agitation in Alzheimer's Dementia: A Randomised Double-Blind Placebo Controlled Trial
    Fox, Chris
    Crugel, Monica
    Maidment, Ian
    Auestad, Bjorn Henrik
    Coulton, Simon
    Treloar, Adrian
    Ballard, Clive
    Boustani, Malaz
    Katona, Cornelius
    Livingston, Gill
    PLOS ONE, 2012, 7 (05):
  • [32] Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison
    McEvoy, Joseph P.
    Lieberman, Jeffrey A.
    Perkins, Diana O.
    Hamer, Robert M.
    Gu, Hongbin
    Lazarus, Arthur
    Sweitzer, Dennis
    Olexy, Christina
    Weiden, Peter
    Strakowski, Stephen D.
    AMERICAN JOURNAL OF PSYCHIATRY, 2007, 164 (07): : 1050 - 1060
  • [33] Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
    Tollefson, GD
    Birkett, MA
    Kiesler, GM
    Wood, AJ
    BIOLOGICAL PSYCHIATRY, 2001, 49 (01) : 52 - 63
  • [34] A 6-week, double-blind comparison of olanzapine, risperidone, and placebo for behavioral disturbance in Alzheimer's disease
    Herz, LR
    Volicer, L
    Frankenburg, F
    Colon, S
    Kittur, S
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1065 - 1065
  • [35] Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease
    Street, J
    Clark, WS
    Gannon, KS
    Mitan, S
    Kadam, D
    Tamura, R
    Tollefson, GD
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 298 - 298
  • [36] Quantitative Analysis of Factors of Attrition in a Double-blind rTMS Study for Alzheimer Treatment
    Bretecher, Carly A.
    Verot, Ashley
    Teschuk, James M.
    Uehara, Maria A.
    Fitzgerald, Paul B.
    Koski, Lisa
    Lithgow, Brian J.
    Moussavi, Zahra
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2024, 38 (03): : 288 - 291
  • [37] The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison
    Keefe, RSE
    Gu, H
    Perkins, D
    Hamer, RM
    Lieberman, JA
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 54 - 54
  • [38] Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
    Czekalla, J
    Beasley, CM
    Dellva, MA
    Berg, PH
    Grundy, S
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (03) : 191 - 198
  • [39] The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison
    Keefe, RSE
    Hongbin, GU
    Sweeney, JA
    Perkins, DO
    McEvoy, JP
    Hamer, RM
    Lieberman, JA
    BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 231S - 232S
  • [40] Olanzapine aggravates parkinsonism: Randomized double-blind study in hallucinating Parkinson's disease patients
    Goetz, CG
    Blasucci, LM
    Leurgans, S
    NEUROLOGY, 2000, 54 (07) : A471 - A471
12345